肿瘤微环境中衰老细胞的可塑性及靶向策略

doi:10.3969/j.issn.1004-616x.2025.04.002

癌变·畸变·突变 ›› 2025, Vol. 37 ›› Issue (4): 268-270,276.doi: 10.3969/j.issn.1004-616x.2025.04.002

• 专题研究 • 上一篇

肿瘤微环境中衰老细胞的可塑性及靶向策略

刘壮壮^1,2, 肖汀²

1. 南方医科大学南方医院, 广东广州 510515;
2. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院, 分子肿瘤学全国重点实验室, 病因及癌变研究室, 北京 100021

收稿日期:2025-04-21 修回日期:2025-05-28 发布日期:2025-08-05
通讯作者: 肖汀
作者简介:刘壮壮，E-mail：liuzhuangzhuang1018@gmail.com。
基金资助:
中国医学科学院医学与健康科技创新工程(2021-I2M-1-050)

Plasticity of senescent cells in the tumor microenvironment and targeting strategies

LIU Zhuangzhuang^1,2, XIAO Ting²

Received:2025-04-21 Revised:2025-05-28 Published:2025-08-05

摘要/Abstract

摘要： 细胞衰老是指细胞处于一种稳定的细胞周期停滞状态，最初被认为是细胞对复制极限的自然应答机制。近年来的研究发现，在肿瘤微环境中衰老可由多种非复制性因素诱导，如氧化应激、癌基因激活及放化疗等，尤其在肿瘤微环境中表现出高度的异质性，不同类型细胞的衰老表型可能在肿瘤进展中发挥相反作用。本文综述了肿瘤微环境中多种细胞成分的衰老特征，重点分析了其在调控肿瘤行为中的功能及机制，并总结了当前靶向衰老细胞的肿瘤治疗策略。

关键词: 细胞衰老, 衰老相关分泌表型, 肿瘤微环境, 靶向治疗

中图分类号:

R730.5

刘壮壮, 肖汀. 肿瘤微环境中衰老细胞的可塑性及靶向策略[J]. 癌变·畸变·突变, 2025, 37(4): 268-270,276.

LIU Zhuangzhuang, XIAO Ting. Plasticity of senescent cells in the tumor microenvironment and targeting strategies[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 268-270,276.

参考文献

[1] HAYFLICK L, MOORHEAD P S. The serial cultivation of human diploid cell strains[J]. Exp Cell Res, 1961, 25: 585-621.
[2] FAGET D V, REN Q H, STEWART S A. Unmasking senescence: context-dependent effects of SASP in cancer[J]. Nat Rev Cancer, 2019, 19(8): 439-453.
[3] WANG B S, HAN J, ELISSEEFF J H, et al. The senescence-associated secretory phenotype and its physiological and pathological implications[J]. Nat Rev Mol Cell Biol, 2024, 25(12): 958-978.
[4] DONG Z N, LUO Y H, YUAN Z C, et al. Cellular senescence and SASP in tumor progression and therapeutic opportunities[J]. Mol Cancer, 2024, 23(1): 181.
[5] COURTOIS-COX S, JONES S L, CICHOWSKI K. Many roads lead to oncogene-induced senescence[J]. Oncogene, 2008, 27(20): 2801-2809.
[6] CHEN Z B, TROTMAN L C, SHAFFER D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis[J]. Nature, 2005, 436(7051): 725-730.
[7] CHANG B D, BROUDE E V, DOKMANOVIC M, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents[J]. Cancer Res, 1999, 59(15): 3761-3767.
[8] EWALD J A, PETERS N, DESOTELLE J A, et al. A high-throughput method to identify novel senescence-inducing compounds[J]. J Biomol Screen, 2009, 14(7): 853-858.
[9] SCHWARZE S R, FU V X, DESOTELLE J A, et al. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells[J]. Neoplasia, 2005, 7(9): 816-823.
[10] ALIMONTI A, NARDELLA C, CHEN Z B, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis[J]. J Clin Invest, 2010, 120(3): 681-693.
[11] ALIMONTI A, CARRACEDO A, CLOHESSY J G, et al. Subtle variations in Pten dose determine cancer susceptibility[J]. Nat Genet, 2010, 42(5): 454-458.
[12] CALCINOTTO A, KOHLI J, ZAGATO E, et al. Cellular senescence: aging, cancer, and injury[J]. Physiol Rev, 2019, 99(2): 1047-1078.
[13] VAN TUYN J, JABER-HIJAZI F, MACKENZIE D, et al. Oncogene-expressing senescent melanocytes up-regulate MHC class II, a candidate melanoma suppressor function[J]. J Invest Dermatol, 2017, 137(10): 2197-2207.
[14] RUSCETTI M, MORRIS J P, MEZZADRA R, et al. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer[J]. Cell, 2021, 184(18): 4838-4839.
[15] ANTONANGELI F, SORIANI A, RICCI B, et al. Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells[J]. Oncoimmunology, 2016, 5(10): e1218105.
[16] VILGELM A E, JOHNSON C A, PRASAD N, et al. Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment[J]. J Natl Cancer Inst, 2015, 108(6): djv406.
[17] LUJAMBIO A, AKKARI L, SIMON J, et al. Non-cell-autonomous tumor suppression by p53[J]. Cell, 2013, 153(2): 449-460.
[18] KUGEL C H 3rd, DOUGLASS S M, WEBSTER M R, et al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations[J]. Clin Cancer Res, 2018, 24(21): 5347-5356.
[19] PALMER D B. The effect of age on thymic function[J]. Front Immunol, 2013, 4: 316.
[20] TOSO A, REVANDKAR A, DI MITRI D, et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity[J]. Cell Rep, 2014, 9(1): 75-89.
[21] OLIVIERI F, SPAZZAFUMO L, SANTINI G, et al. Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging[J]. Mech Ageing Dev, 2012, 133(11/12): 675-685.
[22] KAUR A, ECKER B L, DOUGLASS S M, et al. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility[J]. Cancer Discov, 2019, 9(1): 64-81.
[23] NORTHEY J J, PRZYBYLA L, WEAVER V M. Tissue force programs cell fate and tumor aggression[J]. Cancer Discov, 2017, 7(11): 1224-1237.
[24] LUO X M, FU Y J, LOZA A J, et al. Stromal-initiated changes in the bone promote metastatic niche development[J]. Cell Rep, 2016, 14(1): 82-92.
[25] YOSHIDA A, LEE E K, DIEHL J A. Induction of therapeutic senescence in vemurafenib-resistant melanoma by extended inhibition of CDK4/6[J]. Cancer Res, 2016, 76(10): 2990-3002.
[26] MARTINS C P, BROWN-SWIGART L, EVAN G I. Modeling the therapeutic efficacy of p53 restoration in tumors[J]. Cell, 2006, 127(7): 1323-1334.
[27] RYU S J, OH Y S, PARK S C. Failure of stress-induced downregulation of Bcl-2 contributes to apoptosis resistance in senescent human diploid fibroblasts[J]. Cell Death Differ, 2007, 14(5): 1020-1028.
[28] GUERRERO A, HERRANZ N, SUN B, et al. Cardiac glycosides are broad-spectrum senolytics[J]. Nat Metab, 2019, 1(11): 1074-1088.
[29] AMOR C, FEUCHT J, LEIBOLD J, et al. Senolytic CAR T cells reverse senescence-associated pathologies[J]. Nature, 2020, 583(7814): 127-132.
[30] WANG L Q, LEITE DE OLIVEIRA R, WANG C, et al. High-throughput functional genetic and compound screens identify targets for senescence induction in cancer[J]. Cell Rep, 2017, 21(3): 773-783.

肿瘤微环境中衰老细胞的可塑性及靶向策略

Plasticity of senescent cells in the tumor microenvironment and targeting strategies

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈娇, 刘清, 黄丛改, 郑树涛, 刘涛, 卢晓梅. miR-let-7a-5p靶向调控SNAP23影响食管鳞状细胞癌发展的研究[J]. 癌变·畸变·突变, 2025, 37(1): 63-71.
[2]	张鑫桐, 顾勐, 王子宇, 韦攀健, 王敬慧, 谭金晶. 血糖对EGFR突变肺腺癌患者靶向治疗耐药的影响及其机制[J]. 癌变·畸变·突变, 2024, 36(5): 365-372,383.
[3]	黄韵晓, 顾馨集, 朱梦梅, 于兵. 组蛋白甲基转移酶EZH2及其抑制剂在恶性肿瘤中作用及机制的研究进展[J]. 癌变·畸变·突变, 2024, 36(3): 237-243.
[4]	康文义, 汪献旺, 张为家. CD73在肿瘤免疫逃逸中作用的研究进展[J]. 癌变·畸变·突变, 2024, 36(3): 244-247.
[5]	黄丛改, 刘清, 郑树涛, 刘涛, 谭依依, 彭天元, 陈娇, 卢晓梅. CXCR2在食管癌组织中的表达及其对食管癌细胞生物学行为的影响[J]. 癌变·畸变·突变, 2024, 36(1): 53-57,65.
[6]	刘志彬, 岳文涛. Notch信号通路在卵巢癌中的研究进展[J]. 癌变·畸变·突变, 2023, 35(6): 473-476.
[7]	曹国栋, 曹芳. PI3K/AKT/mTOR信号通路及相关表观遗传调控机制在结直肠癌中的研究进展[J]. 癌变·畸变·突变, 2023, 35(2): 148-153.
[8]	马亚南, 吴楠, 金焰. 肿瘤微环境与卵巢癌化疗耐药机制的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 393-395,400.
[9]	蒋杉, 杜凤, 康秉文, 殷草草, 周健, 石莹, 王玥, 周耿瑶, 秦绪军. 异鼠李素通过减轻氧化应激延缓D-半乳糖诱导的人脐静脉内皮细胞衰老[J]. 癌变·畸变·突变, 2021, 33(2): 95-100.
[10]	郭茜晨, 张婷婷, 王润新, 赵法明, 盛夏. 内质网应激反应IRE1α信号通路与细胞衰老在癌症中的作用及关系的研究进展[J]. 癌变·畸变·突变, 2021, 33(1): 72-76.
[11]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.
[12]	阎琛, 刘清桂, 陈佳佳, 孙宇, 杨桃, 朱海英, 陈费, 王敏君. 移植细胞实现肝脏有效再殖的机制研究[J]. 癌变·畸变·突变, 2020, 32(1): 76-80.
[13]	崔宏伟, 苏秀兰. 胃癌干细胞在胃癌靶向治疗中的研究进展[J]. 癌变·畸变·突变, 2018, 30(6): 490-493.
[14]	郭晓, 王蕊, 吴娟, 纪晓坤, 王珩, 张艳, 马阳, 杜芸. 肺腺癌患者新鲜细胞学标本EGFR基因突变检测及意义[J]. 癌变·畸变·突变, 2018, 30(1): 67-70.
[15]	杨丽, 张小茜, 张孟贤. Notch信号通路对胶质瘤干细胞作用机制的研究进展[J]. 癌变·畸变·突变, 2017, 29(4): 322-324.